Gilead Science vies for purchase of Pharmasset
Biotechnology firm Gilead Sciences, the leading maker of HIV drugs, has announced its plans to acquire a rival firm, Pharmasset, for $11 billion....To view the full article, register now.
Already a subscriber? Click here to view full article